{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:33:04Z","timestamp":1788449584049,"version":"build-2803163510"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100011039","name":"Swiss Centre for Applied Human Toxicology","doi-asserted-by":"publisher","award":["SCAHT-AP_22_01"],"award-info":[{"award-number":["SCAHT-AP_22_01"]}],"id":[{"id":"10.13039\/501100011039","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006392","name":"Centre Hospitalier Universitaire Vaudois","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006392","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Lille Centre of Excellence in Neurodegenerative Disorders"},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["31ND30_213444"],"award-info":[{"award-number":["31ND30_213444"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Neurodegener"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Alzheimer\u2019s disease (AD) is characterized by accumulation of amyloid-\u03b2 (A\u03b2) plaques, tau neurofibrillary Tangles and synaptic dysfunction. The aim of this study was to map the distributions of synaptic vesicle protein 2A (SV2A) and other synaptic proteins in the brain and the brain-derived extracellular vesicles (BDEVs) of AD patients, analyze their associations with A\u03b2, tau, and the apolipoprotein E (<jats:italic>APOE<\/jats:italic>) \u03b54 allele, and investigate the biological role of SV2A.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Mass spectrometry-based proteomics of BDEVs and immunohistochemistry staining were conducted on postmortem brain samples from 57 AD patients and 48 nondemented controls. The levels of SV2A, synaptophysin (SYP), and other synaptic proteins in the brain tissues and the BDEVs, and their associations with A\u03b2, tau (phospho-tau and Braak stages), other proteins and the <jats:italic>APOE<\/jats:italic> \u03b54 allele, were analyzed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>SV2A levels were significantly lower in AD patients than in nondemented controls, particularly in the hippocampus and entorhinal cortex. <jats:italic>APOE<\/jats:italic> \u03b54 carriers presented further reductions in SV2A levels compared with noncarriers. The SV2A levels in BDEVs and brain tissues were positively correlated with SYP levels and negatively correlated with A\u03b2 and phospho-tau levels. Reductions in SV2A were associated with decreased levels of other synaptic proteins, such as synaptotagmins, GAP43, and SNAP25. SV2A emerged as a central hub with interactions with proteins from subnetworks related to synaptic vesicle formation and fusion.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>SV2A levels in brain tissues and BDEVs are reduced in AD patients, particularly in those carrying the <jats:italic>APOE<\/jats:italic> \u03b54 allele, and are correlated with A\u03b2 and tau pathologies. SV2A may serve as a valuable biomarker for monitoring synaptic dysfunction and progression in AD.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s40035-025-00508-2","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T03:55:43Z","timestamp":1758686143000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Reduced synaptic vesicle protein 2A in extracellular vesicles and brains of Alzheimer\u2019s disease: associations with A\u03b2, tau, synaptic proteins and APOE \u03b54"],"prefix":"10.1186","volume":"14","author":[{"given":"Jana","family":"Nussbaumer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aatmika","family":"Barve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin","family":"Zufferey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne","family":"Espourteille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tunahan","family":"Kirabali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Konietzko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Razansky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Rominger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agneta","family":"Nordberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Bu\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morvane","family":"Colin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger M.","family":"Nitsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Hock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Richetin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0793-2113","authenticated-orcid":false,"given":"Ruiqing","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,24]]},"reference":[{"issue":"8","key":"508_CR1","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack Jr.","year":"2024","unstructured":"Jack CR Jr., Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s association workgroup. Alzheimers Dement. 2024;20(8):5143\u201369.","journal-title":"Alzheimers Dement"},{"key":"508_CR2","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.trci.2018.06.014","volume":"4","author":"JW Kinney","year":"2018","unstructured":"Kinney JW, Bemiller SM, Murtishaw AS, Leisgang AM, Salazar AM, Lamb BT. Inflammation as a central mechanism in Alzheimer\u2019s disease. Alzheimers Dement (N Y). 2018;4:575\u201390.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"6","key":"508_CR3","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.jalz.2015.12.005","volume":"12","author":"MC de Wilde","year":"2016","unstructured":"de Wilde MC, Overk CR, Sijben JW, Masliah E. Meta-analysis of synaptic pathology in Alzheimer\u2019s disease reveals selective molecular vesicular machinery vulnerability. Alzheimer\u2019s Dement. 2016;12(6):633\u201344.","journal-title":"Alzheimer\u2019s Dement"},{"issue":"1","key":"508_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41582-022-00749-z","volume":"19","author":"M Tzioras","year":"2023","unstructured":"Tzioras M, McGeachan RI, Durrant CS, Spires-Jones TL. Synaptic degeneration in Alzheimer disease. Nat Rev Neurol. 2023;19(1):19\u201338.","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"508_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-020-00588-4","volume":"12","author":"M Colom-Cadena","year":"2020","unstructured":"Colom-Cadena M, Spires-Jones T, Zetterberg H, Blennow K, Caggiano A, DeKosky ST, et al. The clinical promise of biomarkers of synapse damage or loss in Alzheimer\u2019s disease. Alzheimers Res Ther. 2020;12(1):21.","journal-title":"Alzheimers Res Ther"},{"issue":"6","key":"508_CR6","doi-asserted-by":"publisher","first-page":"3876","DOI":"10.1002\/alz.13817","volume":"20","author":"J Wang","year":"2024","unstructured":"Wang J, Huang Q, He K, Li J, Guo T, Yang Y, et al. Presynaptic density determined by SV2A PET is closely associated with postsynaptic metabotropic glutamate receptor 5 availability and independent of amyloid pathology in early cognitive impairment. Alzheimers Dement. 2024;20(6):3876\u201388.","journal-title":"Alzheimers Dement"},{"issue":"10","key":"508_CR7","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1016\/j.neurobiolaging.2005.09.012","volume":"27","author":"SW Scheff","year":"2006","unstructured":"Scheff SW, Price DA, Schmitt FA, Mufson EJ. Hippocampal synaptic loss in early Alzheimer\u2019s disease and mild cognitive impairment. Neurobiol Aging. 2006;27(10):1372\u201384.","journal-title":"Neurobiol Aging"},{"issue":"6","key":"508_CR8","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.neuron.2010.11.030","volume":"68","author":"BR Hoover","year":"2010","unstructured":"Hoover BR, Reed MN, Su J, Penrod RD, Kotilinek LA, Grant MK, et al. Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron. 2010;68(6):1067\u201381.","journal-title":"Neuron"},{"issue":"5","key":"508_CR9","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/ana.410270502","volume":"27","author":"ST DeKosky","year":"1990","unstructured":"DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer\u2019s disease: correlation with cognitive severity. Ann Neurol. 1990;27(5):457\u201364.","journal-title":"Ann Neurol"},{"issue":"8","key":"508_CR10","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1038\/nn.4328","volume":"19","author":"JW Wu","year":"2016","unstructured":"Wu JW, Hussaini SA, Bastille IM, Rodriguez GA, Mrejeru A, Rilett K, et al. Neuronal activity enhances tau propagation and tau pathology in vivo. Nat Neurosci. 2016;19(8):1085\u201392.","journal-title":"Nat Neurosci"},{"issue":"10","key":"508_CR11","doi-asserted-by":"publisher","first-page":"4244","DOI":"10.1038\/s41380-022-01672-x","volume":"27","author":"G Vanderlinden","year":"2022","unstructured":"Vanderlinden G, Ceccarini J, Vande Casteele T, Michiels L, Lemmens R, Triau E, et al. Spatial decrease of synaptic density in amnestic mild cognitive impairment follows the tau build-up pattern. Mol Psychiatry. 2022;27(10):4244\u201351.","journal-title":"Mol Psychiatry"},{"key":"508_CR12","doi-asserted-by":"publisher","first-page":"15295","DOI":"10.1038\/ncomms15295","volume":"8","author":"L Zhou","year":"2017","unstructured":"Zhou L, McInnes J, Wierda K, Holt M, Herrmann AG, Jackson RJ, et al. Tau association with synaptic vesicles causes presynaptic dysfunction. Nat Commun. 2017;8:15295.","journal-title":"Nat Commun"},{"issue":"1","key":"508_CR13","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1515\/tnsci-2015-0023","volume":"6","author":"J Santosh","year":"2015","unstructured":"Santosh J, Veronika C, Ivana Z, Veronika B, Aladar M, Viera C, et al. Tau-mediated synaptic damage in Alzheimer\u2019s disease. Transl Neurosci. 2015;6(1):214\u201326.","journal-title":"Transl Neurosci"},{"issue":"4","key":"508_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.70004","volume":"10","author":"A Bakker","year":"2024","unstructured":"Bakker A, Rani N, Mohs R, Gallagher M. The HOPE4MCI study: AGB101 treatment slows progression of entorhinal cortex atrophy in APOE \u03b54 non-carriers with mild cognitive impairment due to Alzheimer\u2019s disease. Alzheimers Dement (N Y). 2024;10(4):e70004.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"1","key":"508_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12446","volume":"10","author":"R Mohs","year":"2024","unstructured":"Mohs R, Bakker A, Rosenzweig-Lipson S, Rosenblum M, Barton RL, Albert MS, et al. The HOPE4MCI study: a randomized double-blind assessment of AGB101 for the treatment of MCI due to AD. Alzheimers Dement (N Y). 2024;10(1):e12446.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"647","key":"508_CR16","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abi8593","volume":"14","author":"J Spurrier","year":"2022","unstructured":"Spurrier J, Nicholson L, Fang XT, Stoner AJ, Toyonaga T, Holden D, et al. Reversal of synapse loss in Alzheimer mouse models by targeting mGluR5 to prevent synaptic tagging by C1Q. Sci Transl Med. 2022;14(647):eabi8593.","journal-title":"Sci Transl Med"},{"key":"508_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2024.102197","volume":"94","author":"M Visser","year":"2024","unstructured":"Visser M, O\u2019Brien JT, Mak E. In vivo imaging of synaptic density in neurodegenerative disorders with positron emission tomography: a systematic review. Ageing Res Rev. 2024;94:102197.","journal-title":"Ageing Res Rev"},{"issue":"2","key":"508_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70004","volume":"21","author":"Y Wang","year":"2025","unstructured":"Wang Y, Wang J, Chen X, Lin Z, You Z, He K, et al. Tau pathology is associated with postsynaptic metabotropic glutamate receptor 5 (mGluR5) in early Alzheimer\u2019s disease in a sex-specific manner. Alzheimers Dement. 2025;21(2):e70004.","journal-title":"Alzheimers Dement"},{"issue":"12","key":"508_CR19","doi-asserted-by":"publisher","first-page":"9082","DOI":"10.1002\/alz.14341","volume":"20","author":"F Motolese","year":"2024","unstructured":"Motolese F, Dubbioso R, Ranieri F, Lazzaro VD. Neurophysiological biomarkers of Alzheimer\u2019s disease: in vivo evaluation of synaptic dysfunction. Alzheimers Dement. 2024;20(12):9082\u201384.","journal-title":"Alzheimers Dement"},{"issue":"348","key":"508_CR20","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf6667","volume":"8","author":"S Finnema","year":"2016","unstructured":"Finnema S, Nabulsi N, Eid T, Detyniecki K, Lin S, Chen M, et al. Imaging synaptic density in the living human brain. Sci Transl Med. 2016;8(348):348ra96.","journal-title":"Sci Transl Med"},{"issue":"4","key":"508_CR21","doi-asserted-by":"publisher","first-page":"561","DOI":"10.2967\/jnumed.120.249144","volume":"62","author":"M Naganawa","year":"2021","unstructured":"Naganawa M, Li S, Nabulsi N, Henry S, Zheng M, Pracitto R, et al. First-in-human evaluation of F-SynVesT-1, a radioligand for PET imaging of synaptic vesicle glycoprotein 2A. J Nucl Med. 2021;62(4):561\u20137.","journal-title":"J Nucl Med"},{"issue":"10","key":"508_CR22","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1001\/jamaneurol.2018.1836","volume":"75","author":"M Chen","year":"2018","unstructured":"Chen M, Mecca A, Naganawa M, Finnema S, Toyonaga T, Lin S, et al. Assessing synaptic density in Alzheimer disease with synaptic vesicle glycoprotein 2A positron emission tomographic imaging. JAMA Neurol. 2018;75(10):1215\u201324.","journal-title":"JAMA Neurol"},{"issue":"7","key":"508_CR23","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1002\/alz.12097","volume":"16","author":"A Mecca","year":"2020","unstructured":"Mecca A, Chen M, O\u2019Dell R, Naganawa M, Toyonaga T, Godek T, et al. In vivo measurement of widespread synaptic loss in Alzheimer\u2019s disease with SV2A PET. Alzheimers Dement. 2020;16(7):974\u201382.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"508_CR24","doi-asserted-by":"publisher","first-page":"6356","DOI":"10.1038\/s41467-025-61497-4","volume":"16","author":"Y Luan","year":"2025","unstructured":"Luan Y, Wang W, Huang Q, Wang Y, Nussbaumer J, Wang J, et al. Synaptic loss pattern is constrained by brain connectome and modulated by phosphorylated tau in Alzheimer\u2019s disease. Nat Commun. 2025;16(1):6356.","journal-title":"Nat Commun"},{"key":"508_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116252","volume":"172","author":"Y Kong","year":"2024","unstructured":"Kong Y, Cao L, Xie F, Wang X, Zuo C, Shi K, et al. Reduced SV2A and GABAA receptor levels in the brains of type 2 diabetic rats revealed by [18F]SDM-8 and [18F]flumazenil PET. Biomed Pharmacother. 2024;172:116252.","journal-title":"Biomed Pharmacother"},{"key":"508_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.609908","volume":"9","author":"Y Kong","year":"2021","unstructured":"Kong Y, Huang L, Li W, Liu X, Zhou Y, Liu C, et al. The synaptic vesicle protein 2A interacts with key pathogenic factors in Alzheimer\u2019s disease: implications for treatment. Front Cell Dev Biol. 2021;9:609908.","journal-title":"Front Cell Dev Biol"},{"issue":"5","key":"508_CR27","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.neuron.2011.04.001","volume":"70","author":"SE Kwon","year":"2011","unstructured":"Kwon SE, Chapman ER. Synaptophysin regulates the kinetics of synaptic vesicle endocytosis in central neurons. Neuron. 2011;70(5):847\u201354.","journal-title":"Neuron"},{"issue":"8022","key":"508_CR28","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/s41586-024-07610-x","volume":"631","author":"C Wang","year":"2024","unstructured":"Wang C, Jiang W, Leitz J, Yang K, Esquivies L, Wang X, et al. Structure and topography of the synaptic V-ATPase-synaptophysin complex. Nature. 2024;631(8022):899\u2013904.","journal-title":"Nature"},{"issue":"5","key":"508_CR29","doi-asserted-by":"publisher","first-page":"e545","DOI":"10.1212\/WNL.0000000000009818","volume":"95","author":"H Vanhaute","year":"2020","unstructured":"Vanhaute H, Ceccarini J, Michiels L, Koole M, Sunaert S, Lemmens R, et al. In vivo synaptic density loss is related to tau deposition in amnestic mild cognitive impairment. Neurology. 2020;95(5):e545\u201353.","journal-title":"Neurology"},{"issue":"12","key":"508_CR30","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1002\/alz.12582","volume":"18","author":"A Mecca","year":"2022","unstructured":"Mecca A, O\u2019Dell R, Sharp E, Banks E, Bartlett H, Zhao W, et al. Synaptic density and cognitive performance in Alzheimer\u2019s disease: a PET imaging study with [C]UCB-J. Alzheimers Dement. 2022;18(12):2527\u201336.","journal-title":"Alzheimers Dement"},{"issue":"2","key":"508_CR31","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1007\/s00259-019-04461-x","volume":"47","author":"C Bastin","year":"2020","unstructured":"Bastin C, Bahri MA, Meyer F, Manard M, Delhaye E, Plenevaux A, et al. In vivo imaging of synaptic loss in Alzheimer\u2019s disease with [18F]UCB-H positron emission tomography. Eur J Nucl Med Mol Imaging. 2020;47(2):390\u2013402.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"508_CR32","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/s41380-023-02376-6","volume":"29","author":"S Lista","year":"2024","unstructured":"Lista S, Santos-Lozano A, Emanuele E, Mercuri NB, Gabelle A, L\u00f3pez-Ortiz S, et al. Monitoring synaptic pathology in Alzheimer\u2019s disease through fluid and PET imaging biomarkers: a comprehensive review and future perspectives. Mol Psychiatry. 2024;29(3):847\u201357.","journal-title":"Mol Psychiatry"},{"issue":"1","key":"508_CR33","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41467-023-44374-w","volume":"15","author":"N Franzmeier","year":"2024","unstructured":"Franzmeier N, Dehsarvi A, Steward A, Biel D, Dewenter A, Roemer SN, et al. Elevated CSF GAP-43 is associated with accelerated tau accumulation and spread in Alzheimer\u2019s disease. Nat Commun. 2024;15(1):202.","journal-title":"Nat Commun"},{"issue":"1","key":"508_CR34","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s40035-024-00420-1","volume":"13","author":"W Yi-Ting","year":"2024","unstructured":"Yi-Ting W, Nicholas JA, Stijn S, Johanna N, Marcel SW, Tharick AP, et al. The relation of synaptic biomarkers with A\u03b2, tau, glial activation, and neurodegeneration in Alzheimer\u2019s disease. Transl Neurodegener. 2024;13(1):27.","journal-title":"Transl Neurodegener"},{"issue":"11","key":"508_CR35","doi-asserted-by":"publisher","first-page":"4896","DOI":"10.1002\/alz.13046","volume":"19","author":"P Oeckl","year":"2023","unstructured":"Oeckl P, Bluma M, Bucci M, Halbgebauer S, Chiotis K, Sandebring-Matton A, et al. Blood \u03b2-synuclein is related to amyloid PET positivity in memory clinic patients. Alzheimers Dement. 2023;19(11):4896\u2013907.","journal-title":"Alzheimers Dement"},{"issue":"22","key":"508_CR36","doi-asserted-by":"publisher","first-page":"6309","DOI":"10.1016\/j.cell.2024.08.049","volume":"187","author":"Y Shen","year":"2024","unstructured":"Shen Y, Timsina J, Heo G, Beric A, Ali M, Wang C, et al. CSF proteomics identifies early changes in autosomal dominant Alzheimer\u2019s disease. Cell. 2024;187(22):6309-26.e15.","journal-title":"Cell"},{"issue":"703","key":"508_CR37","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abq5923","volume":"15","author":"YJ Sung","year":"2023","unstructured":"Sung YJ, Yang C, Norton J, Johnson M, Fagan A, Bateman RJ, et al. Proteomics of brain, CSF, and plasma identifies molecular signatures for distinguishing sporadic and genetic Alzheimer\u2019s disease. Sci Transl Med. 2023;15(703):eabq5923.","journal-title":"Sci Transl Med"},{"issue":"5","key":"508_CR38","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1038\/s41591-025-03565-2","volume":"31","author":"HS Oh","year":"2025","unstructured":"Oh HS, Urey DY, Karlsson L, Zhu Z, Shen Y, Farinas A, et al. A cerebrospinal fluid synaptic protein biomarker for prediction of cognitive resilience versus decline in Alzheimer\u2019s disease. Nat Med. 2025;31(5):1592\u2013603.","journal-title":"Nat Med"},{"issue":"3","key":"508_CR39","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1002\/alz.12723","volume":"19","author":"C Tian","year":"2023","unstructured":"Tian C, Stewart T, Hong Z, Guo Z, Aro P, Soltys D, et al. Blood extracellular vesicles carrying synaptic function- and brain-related proteins as potential biomarkers for Alzheimer\u2019s disease. Alzheimers Dement. 2023;19(3):909\u201323.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"508_CR40","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239\u201359.","journal-title":"Acta Neuropathol"},{"issue":"2","key":"508_CR41","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.ymthe.2021.09.020","volume":"30","author":"E Leroux","year":"2022","unstructured":"Leroux E, Perbet R, Caillierez R, Richetin K, Lieger S, Espourteille J, et al. Extracellular vesicles: major actors of heterogeneity in tau spreading among human tauopathies. Mol Ther. 2022;30(2):782\u201397.","journal-title":"Mol Ther"},{"issue":"2","key":"508_CR42","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.12416","volume":"13","author":"JA Welsh","year":"2024","unstructured":"Welsh JA, Goberdhan DC, O\u2019Driscoll L, Th\u00e9ry C, Witwer KW. MISEV2023: an updated guide to EV research and applications. J Extracell Vesicles. 2024;13(2):e12416.","journal-title":"J Extracell Vesicles"},{"issue":"3","key":"508_CR43","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/nmeth.2834","volume":"11","author":"NA Kulak","year":"2014","unstructured":"Kulak NA, Pichler G, Paron I, Nagaraj N, Mann M. Minimal, encapsulated proteomic-sample processing applied to copy-number estimation in eukaryotic cells. Nat Methods. 2014;11(3):319\u201324.","journal-title":"Nat Methods"},{"issue":"12","key":"508_CR44","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1038\/nbt.1511","volume":"26","author":"J Cox","year":"2008","unstructured":"Cox J, Mann M. Maxquant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol. 2008;26(12):1367\u201372.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"508_CR45","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/75556","volume":"25","author":"M Ashburner","year":"2000","unstructured":"Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene ontology: tool for the unification of biology. The gene ontology consortium. Nat Genet. 2000;25(1):25\u20139.","journal-title":"Nat Genet"},{"issue":"1","key":"508_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-9-559","volume":"9","author":"P Langfelder","year":"2008","unstructured":"Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008;9(1):559.","journal-title":"BMC Bioinformatics"},{"issue":"16","key":"508_CR47","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1093\/bioinformatics\/bts366","volume":"28","author":"AC Zambon","year":"2012","unstructured":"Zambon AC, Gaj S, Ho I, Hanspers K, Vranizan K, Evelo CT, et al. GO-elite: a flexible solution for pathway and ontology over-representation. Bioinformatics. 2012;28(16):2209\u201310.","journal-title":"Bioinformatics"},{"issue":"D1","key":"508_CR48","doi-asserted-by":"publisher","first-page":"D631","DOI":"10.1093\/nar\/gkac883","volume":"51","author":"P Lo Surdo","year":"2023","unstructured":"Lo Surdo P, Iannuccelli M, Contino S, Castagnoli L, Licata L, Cesareni G, et al. SIGNOR 3.0, the SIGnaling network open resource 3.0: 2022 update. Nucleic Acids Res. 2023;51(D1):D631\u20137.","journal-title":"Nucleic Acids Res"},{"key":"508_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2023.121593","volume":"321","author":"V Kecheliev","year":"2023","unstructured":"Kecheliev V, Boss L, Maheshwari U, Konietzko U, Keller A, Razansky D, et al. Aquaporin 4 is differentially increased and dislocated in association with tau and amyloid-beta. Life Sci. 2023;321:121593.","journal-title":"Life Sci"},{"issue":"10","key":"508_CR50","doi-asserted-by":"publisher","first-page":"7517","DOI":"10.1007\/s12035-024-04023-9","volume":"61","author":"Z Tang","year":"2024","unstructured":"Tang Z, Chen Z, Guo M, Peng Y, Xiao Y, Guan Z, et al. NRF2 deficiency promotes ferroptosis of astrocytes mediated by oxidative stress in Alzheimer\u2019s disease. Mol Neurobiol. 2024;61(10):7517\u201333.","journal-title":"Mol Neurobiol"},{"issue":"16","key":"508_CR51","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.1002\/cne.24080","volume":"524","author":"SL Ding","year":"2016","unstructured":"Ding SL, Royall JJ, Sunkin SM, Ng L, Facer BA, Lesnar P, et al. Comprehensive cellular-resolution atlas of the adult human brain. J Comp Neurol. 2016;524(16):3127\u2013481.","journal-title":"J Comp Neurol"},{"issue":"1","key":"508_CR52","doi-asserted-by":"publisher","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead P, Loughrey MB, Fern\u00e1ndez JA, Dombrowski Y, McArt DG, Dunne PD, et al. QuPath: open source software for digital pathology image analysis. Sci Rep. 2017;7(1):16878.","journal-title":"Sci Rep"},{"issue":"7","key":"508_CR53","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1093\/brain\/awae032","volume":"147","author":"J Nilsson","year":"2024","unstructured":"Nilsson J, Pichet Binette A, Palmqvist S, Brum WS, Janelidze S, Ashton NJ, et al. Cerebrospinal fluid biomarker panel for synaptic dysfunction in a broad spectrum of neurodegenerative diseases. Brain. 2024;147(7):2414\u201327.","journal-title":"Brain"},{"issue":"7","key":"508_CR54","doi-asserted-by":"publisher","first-page":"4411","DOI":"10.1002\/alz.13823","volume":"20","author":"A Badhwar","year":"2024","unstructured":"Badhwar A, Hirschberg Y, Valle-Tamayo N, Iulita MF, Udeh-Momoh CT, Matton A, et al. Assessment of brain-derived extracellular vesicle enrichment for blood biomarker analysis in age-related neurodegenerative diseases: an international overview. Alzheimers Dement. 2024;20(7):4411\u201322.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"508_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-024-01440-9","volume":"16","author":"X Wang","year":"2024","unstructured":"Wang X, Zhang X, Liu J, Zhang J, Liu C, Cui Y, et al. Synaptic vesicle glycoprotein 2 A in serum is an ideal biomarker for early diagnosis of Alzheimer\u2019s disease. Alzheimers Res Ther. 2024;16(1):82.","journal-title":"Alzheimers Res Ther"},{"key":"508_CR56","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.neurobiolaging.2021.02.012","volume":"103","author":"BM Bettcher","year":"2021","unstructured":"Bettcher BM, Olson KE, Carlson NE, McConnell BV, Boyd T, Adame V, et al. Astrogliosis and episodic memory in late life: higher GFAP is related to worse memory and white matter microstructure in healthy aging and Alzheimer\u2019s disease. Neurobiol Aging. 2021;103:68\u201377.","journal-title":"Neurobiol Aging"},{"issue":"2","key":"508_CR57","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.233019","volume":"313","author":"J Wu","year":"2024","unstructured":"Wu J, Li B, Wang J, Huang Q, Chen X, You Z, et al. Plasma glial fibrillary acid protein and phosphorated tau 181 association with presynaptic density-dependent tau pathology at (18)F-SynVesT-1 brain PET imaging. Radiology. 2024;313(2):e233019.","journal-title":"Radiology"},{"issue":"11","key":"508_CR58","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1001\/jamaneurol.2023.3530","volume":"80","author":"RN Taddei","year":"2023","unstructured":"Taddei RN, Perbet R, de Mate Gerando A, Wiedmer AE, Sanchez-Mico M, Connors Stewart T, et al. Tau oligomer-containing synapse elimination by microglia and astrocytes in Alzheimer disease. JAMA Neurol. 2023;80(11):1209\u201321.","journal-title":"JAMA Neurol"},{"key":"508_CR59","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.neurobiolaging.2021.11.004","volume":"111","author":"AP Mecca","year":"2022","unstructured":"Mecca AP, Chen MK, O\u2019Dell RS, Naganawa M, Toyonaga T, Godek TA, et al. Association of entorhinal cortical tau deposition and hippocampal synaptic density in older individuals with normal cognition and early Alzheimer\u2019s disease. Neurobiol Aging. 2022;111:44\u201353.","journal-title":"Neurobiol Aging"},{"issue":"5","key":"508_CR60","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70333","volume":"21","author":"J Wang","year":"2025","unstructured":"Wang J, Huang Q, Chen X, You Z, He K, Mao X, et al. Prediction of longitudinal synaptic loss in Alzheimer\u2019s disease using tau PET and plasma biomarkers. Alzheimers Dement. 2025;21(5):e70333.","journal-title":"Alzheimers Dement"},{"issue":"2","key":"508_CR61","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14412","volume":"21","author":"G Van derlinden","year":"2025","unstructured":"Van derlinden G, Koole M, Michiels L, Lemmens R, Vandenbulcke M, Van Laere K. Longitudinal synaptic loss versus tau Braak staging in amnestic mild cognitive impairment. Alzheimers Dement. 2025;21(2):e14412.","journal-title":"Alzheimers Dement"},{"issue":"14","key":"508_CR62","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1016\/j.neuron.2023.04.020","volume":"111","author":"M Colom-Cadena","year":"2023","unstructured":"Colom-Cadena M, Davies C, Sirisi S, Lee JE, Simzer EM, Tzioras M, et al. Synaptic oligomeric tau in Alzheimer\u2019s disease\u2014A potential culprit in the spread of tau pathology through the brain. Neuron. 2023;111(14):2170-83.e6.","journal-title":"Neuron"},{"issue":"1","key":"508_CR63","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13195-020-00742-y","volume":"13","author":"RS O\u2019Dell","year":"2021","unstructured":"O\u2019Dell RS, Mecca AP, Chen MK, Naganawa M, Toyonaga T, Lu Y, et al. Association of A\u03b2 deposition and regional synaptic density in early Alzheimer\u2019s disease: a PET imaging study with [(11)C]UCB-J. Alzheimers Res Ther. 2021;13(1):11.","journal-title":"Alzheimers Res Ther"},{"issue":"7","key":"508_CR64","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1177\/0271678X241230733","volume":"44","author":"J Li","year":"2024","unstructured":"Li J, Huang Q, Qi N, He K, Li S, Huang L, et al. The associations between synaptic density and \u201cA\/T\/N\u201d biomarkers in Alzheimer\u2019s disease: an (18)F-SynVesT-1 PET\/MR study. J Cereb Blood Flow Metab. 2024;44(7):1199\u2013207.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"11","key":"508_CR65","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1523\/JNEUROSCI.4970-06.2007","volume":"27","author":"GM Shankar","year":"2007","unstructured":"Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci. 2007;27(11):2866\u201375.","journal-title":"J Neurosci"},{"issue":"1","key":"508_CR66","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.neuron.2018.06.003","volume":"99","author":"A Ittner","year":"2018","unstructured":"Ittner A, Ittner LM. Dendritic tau in Alzheimer\u2019s disease. Neuron. 2018;99(1):13\u201327.","journal-title":"Neuron"},{"issue":"1","key":"508_CR67","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/0304-3940(94)90121-X","volume":"174","author":"E Masliah","year":"1994","unstructured":"Masliah E, Mallory M, Hansen L, DeTeresa R, Alford M, Terry R. Synaptic and neuritic alterations during the progression of Alzheimer\u2019s disease. Neurosci Lett. 1994;174(1):67\u201372.","journal-title":"Neurosci Lett"},{"issue":"11","key":"508_CR68","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1097\/NEN.0b013e318232a379","volume":"70","author":"H Braak","year":"2011","unstructured":"Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol. 2011;70(11):960\u20139.","journal-title":"J Neuropathol Exp Neurol"},{"key":"508_CR69","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.neurobiolaging.2023.05.003","volume":"129","author":"JD Mikkelsen","year":"2023","unstructured":"Mikkelsen JD, Kaad S, Aripaka SS, Finsen B. Synaptic vesicle glycoprotein 2A (SV2A) levels in the cerebral cortex in patients with Alzheimer\u2019s disease: a radioligand binding study in postmortem brains. Neurobiol Aging. 2023;129:50\u20137.","journal-title":"Neurobiol Aging"},{"issue":"1","key":"508_CR70","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s00401-024-02816-9","volume":"148","author":"M Shanaki Bavarsad","year":"2024","unstructured":"Shanaki Bavarsad M, Spina S, Oehler A, Allen IE, Suemoto CK, Leite REP, et al. Comprehensive mapping of synaptic vesicle protein 2A (SV2A) in health and neurodegenerative diseases: a comparative analysis with synaptophysin and ground truth for PET-imaging interpretation. Acta Neuropathol. 2024;148(1):58.","journal-title":"Acta Neuropathol"},{"key":"508_CR71","doi-asserted-by":"publisher","first-page":"538","DOI":"10.3389\/fncel.2019.00538","volume":"13","author":"A Metaxas","year":"2019","unstructured":"Metaxas A, Thygesen C, Briting SRR, Landau AM, Darvesh S, Finsen B. Increased inflammation and unchanged density of synaptic vesicle glycoprotein 2A (SV2A) in the postmortem frontal cortex of Alzheimer\u2019s disease patients. Front Cell Neurosci. 2019;13:538.","journal-title":"Front Cell Neurosci"},{"issue":"4","key":"508_CR72","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1002\/alz.13720","volume":"20","author":"A Kumar","year":"2024","unstructured":"Kumar A, Scarpa M, Nordberg A. Tracing synaptic loss in Alzheimer\u2019s brain with SV2A PET-tracer UCB-J. Alzheimers Dement. 2024;20(4):2589\u2013605.","journal-title":"Alzheimers Dement"},{"issue":"9","key":"508_CR73","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1177\/0271678X211004312","volume":"41","author":"MK Chen","year":"2021","unstructured":"Chen MK, Mecca AP, Naganawa M, Gallezot JD, Toyonaga T, Mondal J, et al. Comparison of [11C]UCB-J and [18F]FDG PET in Alzheimer\u2019s disease: a tracer kinetic modeling study. J Cereb Blood Flow Metab. 2021;41(9):2395\u2013409.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"33","key":"508_CR74","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.1750-23.2024","volume":"44","author":"A Johansen","year":"2024","unstructured":"Johansen A, Beliveau V, Colliander E, Raval NR, Dam VH, Gillings N, et al. An in vivo high-resolution human brain atlas of synaptic density. J Neurosci. 2024;44(33):e1750232024.","journal-title":"J Neurosci"},{"issue":"8","key":"508_CR75","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1177\/0271678X20981502","volume":"41","author":"J van Aalst","year":"2021","unstructured":"van Aalst J, Ceccarini J, Sunaert S, Dupont P, Koole M, Van Laere K. In vivo synaptic density relates to glucose metabolism at rest in healthy subjects, but is strongly modulated by regional differences. J Cereb Blood Flow Metab. 2021;41(8):1978\u201387.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"4","key":"508_CR76","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.tem.2016.12.001","volume":"28","author":"C Lane-Donovan","year":"2017","unstructured":"Lane-Donovan C, Herz J. ApoE, ApoE receptors, and the synapse in Alzheimer\u2019s disease. Trends Endocrinol Metab. 2017;28(4):273\u201384.","journal-title":"Trends Endocrinol Metab"},{"issue":"8","key":"508_CR77","doi-asserted-by":"publisher","DOI":"10.1002\/adtp.202400008","volume":"7","author":"M Wang","year":"2024","unstructured":"Wang M, Zhang Z, Wang Y, Huang L, Huang Q, Ren S, et al. Effect of APOE \u025b4 status on brain amyloid-\u03b2 and cognitive function in amnestic and nonamnestic mild cognitive impairment: a [18F] florbetapir PET-CT study. Adv Ther. 2024;7(8):2400008.","journal-title":"Adv Ther"},{"issue":"12","key":"508_CR78","doi-asserted-by":"publisher","first-page":"8802","DOI":"10.1002\/alz.14327","volume":"20","author":"A Snellman","year":"2024","unstructured":"Snellman A, Tuisku J, Koivum\u00e4ki M, Wahlroos S, Aarnio R, Rajander J, et al. SV2A PET shows hippocampal synaptic loss in cognitively unimpaired APOE \u03b54\/\u03b54 homozygotes. Alzheimers Dement. 2024;20(12):8802\u201313.","journal-title":"Alzheimers Dement"},{"key":"508_CR79","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.neurobiolaging.2021.12.006","volume":"112","author":"LR Taxier","year":"2022","unstructured":"Taxier LR, Philippi SM, York JM, LaDu MJ, Frick KM. The detrimental effects of APOE4 on risk for Alzheimer\u2019s disease may result from altered dendritic spine density, synaptic proteins, and estrogen receptor alpha. Neurobiol Aging. 2022;112:74\u201386.","journal-title":"Neurobiol Aging"},{"issue":"7673","key":"508_CR80","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nature24016","volume":"549","author":"Y Shi","year":"2017","unstructured":"Shi Y, Yamada K, Liddelow SA, Smith ST, Zhao L, Luo W, et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature. 2017;549(7673):523\u20137.","journal-title":"Nature"},{"issue":"10","key":"508_CR81","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1016\/j.neuron.2021.03.024","volume":"109","author":"C Wang","year":"2021","unstructured":"Wang C, Xiong M, Gratuze M, Bao X, Shi Y, Andhey PS, et al. Selective removal of astrocytic APOE4 strongly protects against tau-mediated neurodegeneration and decreases synaptic phagocytosis by microglia. Neuron. 2021;109(10):1657-74.e7.","journal-title":"Neuron"},{"issue":"1","key":"508_CR82","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40478-023-01711-w","volume":"12","author":"I Frigerio","year":"2024","unstructured":"Frigerio I, Bouwman MMA, Noordermeer R, Podobnik E, Popovic M, Timmermans E, et al. Regional differences in synaptic degeneration are linked to alpha-synuclein burden and axonal damage in Parkinson\u2019s disease and dementia with Lewy bodies. Acta Neuropathol Commun. 2024;12(1):4.","journal-title":"Acta Neuropathol Commun"},{"issue":"11","key":"508_CR83","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1038\/s41593-024-01788-z","volume":"27","author":"B Ng","year":"2024","unstructured":"Ng B, Tasaki S, Greathouse KM, Walker CK, Zhang A, Covitz S, et al. Integration across biophysical scales identifies molecular and cellular correlates of person-to-person variability in human brain connectivity. Nat Neurosci. 2024;27(11):2240\u201352.","journal-title":"Nat Neurosci"},{"issue":"9","key":"508_CR84","doi-asserted-by":"publisher","first-page":"3927","DOI":"10.1021\/acschemneuro.9b00351","volume":"10","author":"KA Stout","year":"2019","unstructured":"Stout KA, Dunn AR, Hoffman C, Miller GW. The synaptic vesicle glycoprotein 2: structure, function, and disease relevance. ACS Chem Neurosci. 2019;10(9):3927\u201338.","journal-title":"ACS Chem Neurosci"},{"key":"508_CR85","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.neuroimage.2017.08.035","volume":"197","author":"N Palomero-Gallagher","year":"2019","unstructured":"Palomero-Gallagher N, Zilles K. Cortical layers: Cyto-, myelo-, receptor- and synaptic architecture in human cortical areas. Neuroimage. 2019;197:716\u201341.","journal-title":"Neuroimage"},{"issue":"2","key":"508_CR86","doi-asserted-by":"publisher","first-page":"683","DOI":"10.4103\/NRR.NRR-D-24-01227","volume":"21","author":"R Ni","year":"2026","unstructured":"Ni R. Biomarkers for synaptic dysfunction in Alzheimer\u2019s disease. Neural Regen Res. 2026;21(2):683\u20134.","journal-title":"Neural Regen Res"}],"container-title":["Translational Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40035-025-00508-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40035-025-00508-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40035-025-00508-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T16:04:50Z","timestamp":1758729890000},"score":1,"resource":{"primary":{"URL":"https:\/\/translationalneurodegeneration.biomedcentral.com\/articles\/10.1186\/s40035-025-00508-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,24]]},"references-count":86,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["508"],"URL":"https:\/\/doi.org\/10.1186\/s40035-025-00508-2","relation":{},"ISSN":["2047-9158"],"issn-type":[{"value":"2047-9158","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,24]]},"assertion":[{"value":"7 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the autopsied human brain tissue experiments were carried out in accordance with ethical permission obtained from the regional human ethics committee and the medical ethics committee of the VU Medical Center for NBB tissue. The consent for participation was obtained from the NBB, Lille Neurobank and CHUV.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for publication was obtained from NBB, Lille Neurobank and CHUV.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CH and RMN are employees and shareholders of Neurimmune AG. The authors declare that they have no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"48"}}